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Background: The prognostic relevance of left atrial (LA) morphological and functional variables,
including those derived from speckle tracking echocardiography (STE), has been little investigated
in veterinary medicine.
Objectives: To assess the prognostic value of several echocardiographic variables, with a focus on
LA morphological and functional variables in dogs with myxomatous mitral valve disease (MMVD).
Animals: One-hundred and fifteen dogs of different breeds with MMVD.
Methods: Prospective cohort study. Conventional morphologic and echo-Doppler variables, LA
areas and volumes, and STE-based LA strain analysis were performed in all dogs. A survival
analysis was performed to test for the best echocardiographic predictors of cardiac-related
death.
Results: Most of the tested variables, including all LA STE-derived variables were univari-
ate predictors of cardiac death in Cox proportional hazard analysis. Because of strong
correlation between many variables, only left atrium to aorta ratio (LA/Ao>1.7), mitral
valve E wave velocity (MV E vel>1.3 m/s), LA maximal volume (LAVmax>3.53 mL/kg),
peak atrial longitudinal strain (PALS<30%), and contraction strain index (CSI per 1%
increase) were entered in the univariate analysis, and all were predictors of cardiac death.
However, only the MV E vel (hazard ratio [HR], 4.45; confidence interval [CI], 1.76-11.24;
P< .001) and LAVmax (HR, 2.32; CI, 1.10-4.89; P5 .024) remained statistically significant
in the multivariable analysis.
Conclusions and Clinical Importance: The assessment of LA dimension and function provides
useful prognostic information in dogs with MMVD. Considering all the LA variables, LAVmax
appears the strongest predictor of cardiac death, being superior to LA/Ao and STE-derived
variables.
Abbreviations: Ao, aorta; BW, body weight; CHF, congestive heart failure; CSI, contraction strain index; FAC, fractional area change; LA, left atrium; LAAmax, left
atrial maximal area; LAAmin, left atrial minimal area; LA/Ao, left atrial diameter to aorta ratio; LAVmax, left atrial maximal volume; LAVmin, left atrial minimal
volume; LAEi, left atrial expansion index; LV, left ventricle; LVIDd, left ventricular internal dimension in diastole; LVIDd/Ao, left ventricular internal dimension in
diastole to aorta ratio; LVIDs, left ventricular internal dimension in systole; LVIDs/Ao, left ventricular internal dimension in systole to aorta ratio; MMVD,
myxomatous mitral valve disease; MV E vel, mitral valve E wave velocity; PACS, peak atrial contraction strain; PALS, peak atrial longitudinal strain; STE, speckle
tracking echocardiography; TDI, tissue Doppler imaging; 2D, two-dimensional
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1 | INTRODUCTION
Myxomatous mitral valve disease (MMVD) is the most common cardiac
disease in dogs, with a prevalence of>75% in individuals of specific
canine breeds>5 years of age.1,2 In dogs weighing<9 kg, the most
important cause of death is cardiac-related.3 Therefore, the study of
prognostic indicators of mortality in this population of animals is of pri-
mary importance. Several studies have focused on evaluating clinical
and echocardiographic variables that may predict cardiac mortality in
dogs with MMVD.4–7 Because echocardiography is the most commonly
used diagnostic test in assessing dogs with cardiac disease, it is also the
most studied technique for stratification of dogs with cardiac disease.
Different Doppler variables, two-dimensional (2D) echocardiographic
indicators of mitral valve (MV) pathology, and degree of left atrial (LA)
dilatation are strong predictors of cardiac-related death in dogs with
MMVD.4,5,8 In particular, LA size is easy to measure and strongly asso-
ciated with negative prognosis in affected dogs.4,5,8
Left atrial dimension can be assessed using different echocardio-
graphic methods,9–11 but a recent study has shown that bi-planar-
derived LA volume is superior to traditional simple LA diameter in
predicting LA dilatation in dogs with MMVD.12 Until now, survival
studies have considered only LA diameter and its ratio to aortic root
diameter (Ao; [LA/Ao]) as predictors of survival.4–6 Canine and feline
LA function has been non-invasively estimated with echocardiography
using several approaches, such as measuring LA fractional shortening,
LA fractional area change (FAC), and LA ejection fraction (EF).13–16
Assessment of atrial deformation profiles obtained using tissue Doppler
imaging (TDI) and its derived variables, strain and strain rate, recently
has been proposed as an alternative method of exploring LA mechanics
both in humans17–19 and dogs.20 Nevertheless, a number of potential
drawbacks of this approach should be considered, including suboptimal
reproducibility, angle dependence, and the confounding effect of noise
artifacts.17–20 Many of these limitations may be overcome by using 2D
speckle tracking echocardiography (STE), the most recent and promis-
ing ultrasound technology for direct evaluation of LA function from
standard gray-scale echocardiographic images.17–19 Until now, only a
few studies have used STE in evaluating LA function both in healthy21
and diseased dogs,15,22 highlighting a progressive decrease in LA func-
tion according to the progression of MMVD class. Decreased LA func-
tion also has been recognized as a valuable prognostic indicator in dogs
with MMVD.23 However, studies comparing different echocardio-
graphic variables, particularly those of LA dimension and function, as
predictors of cardiac mortality in dogs with MMVD are lacking.
Therefore, the aims of our study were: (1) to investigate the prog-
nostic value of LA STE variables on survival in dogs with MMVD; and,
(2) to compare the usefulness of different echocardiographic variables,
particularly those related to LA dimension and function, as predictors
of cardiac mortality in dogs with MMVD.
2 | MATERIALS AND METHODS
2.1 | Animals
Dogs had been examined during a previous study evaluating LA defor-
mation and function using STE in a larger group of dogs, and only those
with MMVD and follow-up available were enrolled in the present
study.15 Dogs were presented to the cardiology unit of the Veterinary
Teaching Hospital of the University of Bologna for cardiac evaluation
on the basis of cardiac murmur clarification, clinical signs referable to
heart disease (eg, dyspnea, cough, syncope), for breed screening, or for
preanesthetic evaluation. Dogs were prospectively recruited from Janu-
ary 2011 to December 2014 and included in the study if they had clini-
cal and echocardiographic signs typical for MMVD and body weight
(BW)<21 kg. Only dogs with follow-up information available, as stated
in the following sections, were included. Dogs with congenital cardiac
malformations, dilated cardiomyopathy, or other acquired cardiac dis-
eases were not included. Only dogs in sinus rhythm were included in
the study. Dogs were allowed to receive medications for congestive
heart failure (CHF) if considered necessary by the clinician. Thoracic
radiography in 2 perpendicular projections was performed to exclude
or confirm the presence of CHF (eg, pulmonary edema) to guide medi-
cal treatment.
2.2 | Procedures and assessment of LA dimension and
function
All dogs underwent complete clinical examination and cardiac ausculta-
tion. Complete transthoracic echocardiography was performed accord-
ing to standard techniques24 by 2 investigators (MBT, MC) with several
years of expertise in echocardiography, using ultrasound units (a iU22
ultrasound system, Philips Healthcare, Monza, Italy; iE33 ultrasound
system, Philips Healthcare, Monza, Italy) equipped with phased array
transducers of various frequencies and continuous ECG tracing. All of
the examinations then were reviewed by a single experienced cardiolo-
gist (MBT). The diagnosis of MMVD was made on the basis of clinical
examination and echocardiographic criteria including thickening or pro-
lapse of the MV leaflets or both on 2D echocardiography and mitral
regurgitation on color Doppler examination. Chamber diameters of the
left ventricle (LV) were obtained from 2D-guided M-mode images
acquired from a right parasternal short axis view at the level of the pap-
illary muscles and then indexed to the Ao,25 measured from a right par-
asternal short axis view. The LA and Ao were measured on 2D images
obtained from a right parasternal short axis view at the basilar level just
after Ao valve closure, and the LA/Ao was calculated.9 The LV diastolic
inflow was recorded from the left apical 4-chamber view, placing the
sample volume at the level of the tips of the MV on the ventricular
side. Three consecutive measurements were averaged for each
variable.
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For the analysis of LA areas, volumes, and STE, the left apical 4-
chamber view was optimized to perfectly visualize the LA walls. Then,
a 3-consecutive cardiac beats cine-loop was acquired and stored in
Digital Images and Communications in Medicine format for subsequent
analysis. Dedicated software (OsiriX MD Software, Pixeo SARL,
Geneva, Switzerland) was used to review the video clips, the beat with
the best image quality was chosen, and the endocardial border of the
LA was traced during maximal (just before the MV opening) and mini-
mal (just before the MV closure) LA expansion and LA areas were pro-
vided. Accordingly, end systolic and end diastolic LA lengths were
measured, starting from the MV annulus to the atrial roof. The aortic
cross sectional-area (AoArea) was obtained by tracing the internal bor-
der of the aorta at the level of the cusps at end systole from a right
parasternal short axis view. Left atrial maximal area (LAAmax) and mini-
mal area (LAAmin) expressed in cm2 were automatically calculated by
the software and then indexed to the AoArea. Left atrial fractional area
change then was calculated using the formula: FAC5 ([LAAmax –
LAAmin]/LAAmax) 3 100, and expressed as a percentage.15 Left atrial
maximal (LAVmax) and minimal (LAVmin) volume was calculated using
the monoplane area-length method using the formula: LAV5 (0.85 3
A1 3 A1)/L, where A1 is the LAA and L is LA length.11 Left atrial vol-
umes then were indexed to BW and expressed in mL/kg. Left atrial
expansion index (LAEi) was calculated using the formula: ([LAVmax –
LAVmin]/LAVmin) and expressed as a percentage.13
The same cine-loops and beats used to measure LA areas and vol-
umes were successively employed for the STE analysis using dedicated
software (QLAB quantification software version 9.1, Philips Healthcare,
Monza, Italy.) as previously described.15 Briefly, the operator selected 3
points on the LA (2 on the MV annulus and 1 on the LA roof) and the
software automatically drew a region of interest on the entire LA wall
dividing it into 7 regions (from the basilar segments to the roof of the
LA), and manual editing was done if necessary. Those segments that
showed artifactual values (because of the lung interposition or echo
drop-out at the level of the region of the fossa ovalis or the pulmonary
veins inlet) were excluded from the analysis. Time/intensity curves
then were generated for each segment displacing strain values (as per-
centages) on the y-axis and time (in seconds) on the x-axis over an
entire cardiac cycle. The software also generated a mean curve of all
the segments that was used by the operator to measure the peak strain
value during LV contraction (peak atrial longitudinal strain [PALS]), and
just before LA active contraction, on the peak of the P wave of the
ECG trace (peak atrial contraction strain [PACS]). Finally, the contrac-
tion strain index (CSI) was calculated using the formula: CSI5 ([PALS/
PACS] 3 100; Figure 1). This last variable represents the contribution
of LA contraction to LV filling.15 The entire image analysis was per-
formed by a single operator (MBT). Representative images showing
how region of interest of LA area, volumes, and STE were drawn are
shown in Figure 1.
2.3 | Survival analysis
Survival data were obtained from an internal database or by telephone
questionnaires. Dogs were classified as still alive, dead for cardiac-
unrelated causes, or dead for cardiac-related causes (defined as sudden
death, CHF refractory to medical treatment, euthanasia because of
worsening cardiac condition, or death within 2 hours from the onset of
pulmonary edema).4 Time in days from the echocardiographic examina-
tion to the phone call for dogs still alive (follow-up time) or to death
(survival time) was recorded.
2.4 | Statistical analysis
Descriptive statistics were used for age, sex, and BW. Normal distribu-
tion of the echocardiographic, echo-Doppler, and STE-derived variables
was assessed using a Shapiro-Wilks test. Data were reported as
FIGURE 1 A, Representative images from a dog included in the
study, showing how region of interest of LA area, volumes, and
STE were drawn. Endocardial border tracing and length
measurement of LA in left apical 4-chamber view at end systole
(maximal dimensions). The software automatically gives the LA
area. The same procedure was then repeated at end diastole (mini-
mal dimensions). Left atrial volume was then calculated using the
monoplane area-length formula, by measuring the LA area (A1) and
length (L). B, LA STE analysis obtained from left apical 4-chamber
view. A region of interest is manually drawn to include the LA wall,
which is automatically divided into seven different segments with
different colors. LA, left atrium; LV, left ventricle; STE, speckle
tracking echocardiography
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mean6 standard deviation (SD) or as median (min-max) if variables
were normally or not normally distributed, respectively.
The approach used to analyze days of survival after diagnosis was
that previously reported.8 Dogs still alive at the end of the study and
dogs that died for noncardiac related events were right-censored. The
effect of each predictive variable on survival time was evaluated using
Kaplan-Meier survival analysis. Predictive continuous variables were
divided into quartiles. Pairwise post-hoc log-rank analyses were per-
formed across the quartiles of variables to identify significant differen-
ces among them. Cut-off values were based on significantly different
sequential quartiles and were used to dichotomize each variable. Varia-
bles showing an ordinal increase or decrease in the hazard within each
quartile were taken forward to the multivariable analysis as continuous
data, whereas variables not significant on Kaplan-Meier analysis were
not further considered. Hazard ratios (HR) and 95% confidence inter-
vals (CI) for the Cox univariate factors were calculated using the Cox
proportional hazards model. The association between predictors was
evaluated using the Spearman’s rank correlation index (r). For any pair
of variables with a correlation coefficient (r)> .8, only 1 variable (that
with the greatest Wald chi-square in the Cox univariate analysis) was
kept for further analyses. Variables with P< .2 in univariate analysis
were entered into a Cox regression multivariable analysis using a man-
ual forward selection method to identify independent predictors of sur-
vival. The variable with the most significant association with cardiac
death (ie, lowest P value) was entered into the model at each iteration.
The order in which variables were entered into the model was based
on the strength of their association, and those with the lowest P values
from the previous step entered first. Goodness-of-fit of the model was
evaluated using Akaike criteria. The assumptions of the model were vis-
ually inspected using graphical representation of the residuals. All sta-
tistical analyses were performed using 2 commercial dedicated
software programs (SAS version 9.3, SAS Institute Inc, Cary, North
Carolina; MedCalc version 12.6.1.0, MedCalc Software, Ostend, Belgium).
Measurements of all STE variables (PALS, PACS, CSI, LAAmax,
LAAmin, and FAC) previously had shown good intraobserver and inter-
observer repeatability in our laboratory.15 Because LA volumes were
directly derived from LA areas measurements, variability analysis of
these variables was not performed.
3 | RESULTS
One-hundred fifteen dogs met the inclusion criteria of the study.
Descriptive statistics and echocardiographic variables are summarized
in Table 1. At the time of inclusion, 37 dogs were in CHF confirmed by
thoracic radiography, and they were clinically stable under medical
treatment. None of the other animals experienced CHF before or at
inclusion. Drugs used to control clinical signs of CHF were: 37 dogs
received benazepril (mean dosage, 0.38 mg/kg q12–24h); 35 dogs
received pimobendan (mean dosage, 0.31 mg/kg q12h); 5 dogs
received amlodipine (mean dosage, 0.3 mg/kg q24h); 3 dogs received
spironolactone (mean dosage, 2 mg/kg q24h); and 37 dogs received
furosemide (mean dosage, 2 mg/kg q12h; Table 1).
At the end of the follow-up period, 35 dogs had died because of
cardiac-related causes (median survival, 212 days; range, 16–1,179
days), 28 dogs had died of non cardiac-related causes (median survival,
318 days; range, 81–1,067 days), and 52 dogs were still alive (median
follow-up, 539 days; range, 151–1,259 days).
Each Kaplan-Meier survival curve was calculated (the curves of the
variables that were not significant in the multivariable analysis are pre-
sented as on-line supporting information). The following variables were
dichotomized: LA/Ao, MV E vel, LAVmax, PALS, LAAmax/Ao, LAAmin/
Ao, LAVmin, and PACS, whereas CSI, LVIDs/Ao, and LVIDd/Ao were
considered in the following analyses as continuous predictive variables
(Table 2). The LAEi and LA FAC were not significantly associated with
survival time and were not considered in further analyses. Of the above
considered variables, only LVIDs/Ao was not a significant predictor of
survival in the Cox univariate analysis. The LAAmax/Ao, LAAmin/Ao,
and LAVmin were not further considered in the following evaluations
because of their high correlation with LAVmax (r5 .87, r5 .84, and
r5 .94, respectively). In the same way, PACS was excluded from the
multivariable analysis because it was highly correlated with CSI (r5 .80)
and similarly LVIDd/Ao was highly correlated with LA/Ao (r5 .85). The
LA/Ao, MV E vel, LAVmax, PALS, and CSI were retained as significant
predictors after multivariable analysis. The risk of event increased with
higher values of LA/Ao, MV E vel, and LAVmax, and with lower values
of PALS, whereas it decreased with higher values of CSI (Table 2).
When these variables were entered into the multivariable model, only
MV E vel>1.3 m/s and LAVmax>3.53 mL/kg were retained with HRs
of 4.45 (CI, 1.76-11.24; P< .001) and 2.32 (CI, 1–4.89; P5 .024),
respectively (Table 3). The Kaplan-Meier curves for the variables that
were significant in the multivariable analysis are presented in Figure 2.
4 | DISCUSSION
We evaluated the prognostic value of several echocardiographic varia-
bles on survival in dogs with MMVD. In particular, we focused on LA
morphological and functional variables, also including for the first time
in veterinary medicine some STE-derived variables.
The survival analysis showed that STE-derived LA strain and the
related variables PALS, PACS, and CSI are univariate predictors of
cardiac-related death in dogs with MMVD, but these parameters lost
prognostic significance in multivariable analysis. Only MV E
vel>1.3 m/s and LAVmax>3.53 mL/kg were independent predictors
of high mortality risk. The association between increased MV E vel and
poor prognosis in dogs with MMVD already has been demonstrated,
with cut-off values of 1.2 and 1.4 m/s, depending on the study.4,5,8,26
Moreover, increasing MV E vel values over serial examinations also
have been associated with a poorer outcome.27 Mitral valve E vel is
determined mainly by LV filling pressures and relaxation.28 In cardiac
disease, such as MMVD, where the preload is disproportionally
increased, the filling pressure component is dominant on relaxation.
Therefore, an increase in MV E vel is an indirect measure of mitral
regurgitation severity, reflecting worsening pressure differences
between the LA and LV with increasing regurgitant volumes.8,28 Not
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surprisingly, the 2 variables that better reflect increased LA preload,
namely MV E vel and LAVmax, were both predictors of cardiac death
in the multivariable analysis.
Regarding LA measurement, LA/Ao was an independent predictor
of a poor prognosis in the first study on clinical and echocardiographic
predictors of mortality in dogs with MMVD,4 but this finding was not
confirmed in a more recent study.8 Our findings about the negative
prognostic value of LAVmax, but not of LA/Ao, might suggest that the
use of linear measurements to predict LA enlargement may underesti-
mate the risk stratification of dogs with MMVD. Although LA/Ao has
TABLE 1 Descriptive statistics of 115 dogs with MMVD
Variable Observed values N Reference range Reference #
Age (years) 10.96 3.3
















LVIDd/Ao 2.26 0.5 1.660.2 25
LVIDs/Ao 1.26 0.3 1.160.2 25
MV E vel (cm/s) 105.56 39.8 71.365.64 15
LA/Ao 1.86 0.4 <1.5 12
LAAmax/Ao 4.36 2.5 2.2 (1.9-2.4) 15
LAAmin/Ao 2.66 1.8 0.9 (0.8-1.1) 15
LA FAC (%) 42.66 9.7 55.162.09 15
LAVmax (mL/kg) 2.86 2.0 0.58 (0.92)a 13
LAVmin (mL/kg) 1.46 1.3 0.21 (0.38)a 13
LAEi (%) 95.36 70.5 173 (76–394) 13
PALS (%) 40.96 13.8 60.462.36 15
PACS (%) 18.16 10.1 26.361.77 15
CSI (%) 42.26 17.2 42.863.24 15
Drugs for CHF N Mean dose (mg/kg)
Furosemide 37 2 q12h
Benazepril 37 0.38 q12–24h
Pimobendan 35 0.31 q12h
Spironolactone 3 2 q24h
Amlodipine 5 0.30 q24h
Data are expressed as mean6 SD or median (min-max).
Abbreviations: CHF, congestive heart failure; CKCS, Cavalier king Charles spaniel; CSI, contraction strain index; LA/Ao, left atrial diameter to aorta ratio;
LAEi, left atrial expansion index; LA FAC, left atrial fractional area change; LAAmax/Ao, left atrial maximal area to aortic area ratio; LAAmin/Ao, left
atrial minimal area to aortic area ratio; LAVmax, left atrial maximal volume indexed to body weight; LAVmin, left atrial minimal volume indexed to body
weight; LVIDd/Ao, left ventricular internal dimension in diastole to aorta ratio; LVIDs/Ao, left ventricular internal dimension in systole to aorta ratio;
MV E vel, mitral valve E wave peak velocity; N, number of dogs; PALS, peak atrial longitudinal strain; PACS, peak atrial contraction strain
aReported as mean (95th percentile).
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been proven to predict cardiac-related death in dogs with MMVD,4 the
volumetric approach of measuring the LA seems more effective in pre-
dicting mortality. In humans, presence of LA dilatation correlates with
increased risk of developing stroke, atrial fibrillation, and cardiac-related
death.29 Therefore, detecting cardiac chamber dilatation is crucial for
stratifying patients with cardiac disease, and the recommended way to
assess LA dilatation in people now is the use of volumetric methods.30
In cats with cardiac disease, LA volume and LA EF, obtained from
volume measurement over the cardiac cycle, have been reported to be
useful diagnostic and prognostic echocardiographic variables, showing
better performance when compared to simple diameter measure-
ments.31 One study comparing LA/Ao with LA volume assessment in a
population of dogs with MMVD showed that mild LA dilatation could be
detected in some dogs only by measuring LA volume, but not LA diame-
ter.12 Results of our study confirm that the use of a volumetric method
also has prognostic relevance in assessing LA dimension in dogs com-
pared to standard linear measurement. Whether this kind of measure-
ment is reproducible among different cardiologists at different centers
still must be clearly elucidated. At present, studies from 2 different
research groups have shown acceptable reproducibility in assessing LA
volumes both in healthy dogs10,13 and dogs with MMVD.11
Among the variables of LA function, only STE-derived variables
were predictors of cardiac related death in our population of dogs,
whereas LA FAC and LAEi were not (Figure 2). This finding is in con-
trast with a previous study where LA FAC appeared to be a prognostic
factor within 1 year in dogs with MMVD.23 In that study, a different
type of statistical analysis was carried out, with a direct comparison of
LA FAC values between dogs that were dead or alive at 1 year after
inclusion. In our study, STE-derived PALS, PACS, and CSI were all uni-
variate predictors of survival. Left atrial strain recently has been studied
to validate the technique in clinically healthy dogs21 and to evaluate
strain changes in dogs under experimental conditions,32,33 or in dogs
with naturally occurring MMVD.15,22 With progression of disease, STE-
derived variables tend to decrease as a consequence of progressive
impairment in LA contraction and relaxation.15,22 This might be second-
ary to changes in loading conditions, LA preload and afterload, and
TABLE 2 Cox proportional hazard univariate analysis in 115 dogs
with MMVD
Variable HR 95% CI P
LA/Ao>1.7 5.10 2.41-10.8 <.001
MV E vel>1.3 m/s 6.49 2.76-15.25 <.001
LAAmax/Ao>3.6 4.69 2.35-9.36 <.001
LAAmin/Ao>2 5.02 2.51-10.03 <.001
LAVmin> 1.5 mL/kg 5.46 2.75-10.83 <.001
LAVmax>3.53 mL/kg 4.53 2.28-8.99 <.001
PALS<30% 3.11 1.58-6.12 .001
PACS<11% 3.05 1.55-6.03 .001
LVIDd/Ao per 0.1 increase 3.87 1.98-7.52 <.001
LVIDs/Ao per 0.1 increase 1.67 0.47-5.83 .420
CSI per 1% increase 0.97 0.95-0.99 .007
Abbreviations: CI, confidence interval; CSI, contraction strain index; HR,
hazard ratio; LA/Ao, left atrium to aorta ratio; LAAmax/Ao, left atrial
maximal area to aortic area; LAAmin/Ao, left atrial minimal area to aortic
area; LAVmin, left atrial maximal volume indexed to body weight; LAV-
max, left atrial minimal volume indexed to body weight; LVIDd/Ao, left
ventricular internal dimension in diastole to aorta ratio; LVIDs/Ao, left
ventricular internal dimension in systole to aorta ratio; MV E vel, mitral
valve E wave peak velocity; PALS, peak atrial longitudinal strain; PACS,
peak atrial contraction strain
TABLE 3 Final model results in the multivariable cox proportional
hazard analysis in 115 dogs with MMVD
Variable HR 95% CI P
MV E vel>1.3 m/s 4.45 1.76-11.24 <.001
LAVmax>3.53 mL/kg 2.32 1.10-4.89 .024
Abbreviations: CI, confidence interval; HR, hazard ratio; LAVmax, left
atrial maximal volume indexed to body weight; MV E vel, mitral valve E
wave peak velocity.
FIGURE 2 Kaplan-Meier survival curves of the two variables that remained significant in the multivariable analysis for 115 dogs with
myxomatous MV disease. E vel, E wave velocity; LAVmax, left atrial maximal volume
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progressive LA fibrosis that occur during MMVD.15,34 In people, LA
strain analysis is useful for stratifying patients with valvular disease,
atrial fibrillation, or acute coronary disease.35–37 Moreover, LA strain
has been shown to be an independent predictor of death or the need
for cardiac transplantation in people with symptomatic systolic
dysfunction.38 Our study is the first in veterinary medicine to show
that, similarly to people, STE-derived strain can be used as a prognostic
indicator also in dogs with cardiac disease, namely MMVD.
Our study had some limitations. We focused mainly on echocar-
diographic indicators of LA morphology and function, without introduc-
ing echocardiographic variables of MV pathology into the analysis, the
radiographically derived vertebral heart score, or clinical variables, such
as syncope, presence of heart murmur, presence of CHF, and dyspnea,
that are known to be independent prognostic indicators in dogs with
MMVD.4,7,8,39 Moreover, for the assessment of LA volume we used
the monoplane area-length method obtained from the 4-chamber view.
In people, the bi-plane method from the 4- and 2-chamber views is
preferred to derive LA volumes.30 However, studies in dogs have
shown that use of a monoplane method overestimates the volume by
only 5.8% when compared with the bi-plane method.11 Moreover, a
strong correlation exists among different methods of calculation of LA
volumes in dogs when using 2D echocardiographic images.10,11 There-
fore, different echocardiographic approaches in measuring LA volumes
in dogs appear interchangeable in the clinical setting, and it appears
unlikely that the method we chose negatively affected our results.
Another possible limitation to our study is the use of a single cardiac
cycle to perform the STE analysis. Whether the beat-to-beat variation
and sinus arrhythmia could significantly affect LA STE-derived variables
in dogs remains to be elucidated in further studies. Finally, the effect of
cardiac medication and diuretics on LA function and STE-derived varia-
bles has not been investigated. In clinically healthy dogs, experimentally
induced volume overload enhances LA phasic function because of the
increased preload, according to the Frank-Starling mechanism.32 How-
ever, in naturally occurring disease, LA phasic function decreases with
the progression of the disease, likely in response to the presence of
other concurrent mechanisms, such as increased LA afterload and LA
fibrosis.15 It might be speculated that using some medications that
decrease LA pressure (eg, furosemide, angiotensin converting enzyme
inhibitors, amlodipine, pimobendan)39–43 could have an effect on LA
function, leading to some bias when comparing untreated dogs with LA
dilatation and dogs under medical treatment. To prove whether or not
this assumption is correct requires further studies.
In conclusion, we evaluated the prognostic significance of several
echocardiographic variables of LA morphology and function in dogs
with MMVD. Although many variables, including all STE variables, were
able to predict mortality in this population of animals, only MV E
vel>1.3 m/s and LAVmax>3.53 mL/kg remained significant predic-
tors of cardiac death in the multivariable analysis.
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